Current preclinical cancer animal models are poorly predictive in clinical efficacy, and have limited value in predicting disease indications in human. Primary tumor tissue offers a valuable resource for biomarker identification, as well as a better alternative for preclinical drug evaluation. However, accessing sufficient high quality tumor tissue remains a significant challenge for translational research. Furthermore, establishing testing system from primary tumor samples is often cost inhibitive due to low success rate and high labor intensity in the process.

Crown Bioscience Inc. has extensive experience in establishing primary cell lines and tumor models. Through our exclusive partnership with Shanghai Tigermed Consulting, Ltd, a leading oncology clinical CRO based in China, we have established extensive network with major Chinese cancer hospitals. And we have access to advanced analytical capability to identify complex gene/protein expression signatures that are unique for each cancer type.

Our service can help pharmaceutical companies prioritize lead compounds, narrow down possible disease indication, and identify biomarkers to stratify patient populations in clinical trials, thus lowering drug attrition rate and reducing development cost.

Capabilities in cancer translational research

• High quality human cancer tissue procurement with detailed clinical background information
• Derivation of primary human cancer cell lines
• Establishment of in vivo cancer animal models with fresh human tumor tissues
• Primary tumor tissue gene expression profiling
• Protein expression profiling via LC-MS/MS
• Biomarker discovery and validation
• Target validation with primary human cells and tumors
• In vitro/in vivo drug prioritization through primary tumor derived cancer models